At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
-
Nov 29, 2018
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced that it has entered into a securities purchase agreement with an institutional investor, providing...
-
Nov 21, 2018
All objectives from the Phase 1/1b study successfully met, on track to initiate a Phase 2 study in asthmatic patients with allergic bronchopulmonary aspergillosis (ABPA) in 2018
Pulmatrix, Inc. (NASDAQ: PULM) announced the results of the completed first-in-human study of Pulmazole (PUR1900) — an inhaled iSPERSETM formulation of the anti-fungal drug itraconazole for the...
-
Nov 15, 2018
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases will present the results of the recently...
-
Nov 14, 2018
Pulmatrix, Inc. (NASDAQ: PULM) today reported its third quarter results. "We remain focused on advancing the clinical development of our Pulmazole program," said Robert W. Clarke, Ph.D., chief...
-
Sep 17, 2018
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases will present preclinical data on the...
-
Aug 28, 2018
Pulmatrix, Inc. (NASDAQ: PULM) will present at the Rodman & Renshaw 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 10:00 AM EDT in the Lotte New York Palace Hotel in...
-
Aug 3, 2018
Pulmatrix, Inc. (NASDAQ: PULM) today reports its second quarter results. "We are pleased with the preliminary results of the three-part Phase 1/1b clinical trial of Pulmazole. The data supports...
-
Jul 23, 2018
Members include experts in both clinical research and management of Allergic Bronchopulmonary Aspergillosis and Asthma
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today the formation of the...
-
Jul 17, 2018
Single dose of Pulmazole safe and well tolerated in subjects with asthma
Pulmatrix, Inc. (NASDAQ: PULM) announced today that all dosing and follow up visits have been completed for Part 3 of the ongoing first-in-human study of Pulmazole (PUR1900) - an inhaled iSPERSETM...
-
Jun 25, 2018
All doses were well tolerated in normal healthy volunteers in Parts 1 and 2 at up to 35 mg of itraconazole, the maximal dose planned
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today top-line results for the...
-
Jun 13, 2018
Data published in the British Journal of Clinical Pharmacology demonstrate that PUR0200 achieves similar improvements in lung function to Spiriva® HandiHaler® at significantly lower doses
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today the publication of data...
-
Jun 7, 2018
No Imminent Plan to Effect Reverse Stock Split
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that each of the following...
-
May 17, 2018
Company will also present pre-clinical data on RV1162 (PUR1800) at the affiliated American Thoracic Society 2018 International Conference in San Diego
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases has been selected to present at the 2018...
-
May 11, 2018
Pulmatrix, Inc. (NASDAQ: PULM) today reports its first quarter results. "We reached a major milestone for our Pulmazole program in the first quarter with the initiation of dosing in our phase 1/1b...
-
Mar 29, 2018
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the pricing of an underwritten public offering of an aggregate of 23,500,000 units. Each unit is...
-
Mar 13, 2018
Pulmatrix, Inc. (NASDAQ: PULM) today announces 2017 financial results, reviews the Company's recent progress, and provides an outlook for its pulmonary disease development pipeline. "The Company...
-
Feb 12, 2018
Phase 1 data is expected in mid-2018
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that the single dose...
-
Jan 24, 2018
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that it will present new...
-
Jan 22, 2018
Screening of subjects for this first-in-human study has begun and represents an important milestone in advancing this first in class therapy to the clinic
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that it has received...
-
Nov 9, 2017
Completed Out-License Agreement for PUR0200 US Rights and Received Award to Advance Development of Pulmazole
Pulmatrix, Inc. (NASDAQ: PULM) today reports its third quarter financial results and provided an overview of recent operational highlights. "During the third quarter, we made significant progress...
-
Oct 31, 2017
Preclinical data show that Pulmatrix's inhaled antifungal drug can achieve high concentrations in the lungs, with low levels in the bloodstream
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it will present...
-
Oct 30, 2017
Dr. Roach will help Pulmatrix accelerate the development of its innovative inhaled drugs
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has appointed...
-
Oct 3, 2017
The FDA designation provides five years of market exclusivity for Pulmatrix's inhaled product for treating fungal infections in the lungs of patients with allergic bronchopulmonary aspergillosis
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that its drug candidate...
-
Sep 21, 2017
Pulmatrix, Inc. (NASDAQ: PULM) will present at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017 at 2:15 PM EDT in the Intercontinental New York Barclay Hotel in...
-
Sep 20, 2017
The patents broaden the protection and potential applications for Pulmatrix's innovative inhaled drug delivery platform and most advanced drug candidate
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received two...
|
home about pulmatrix platform pipeline investors careers contact site design